Survival outcomes for elderly lymphoma patients are disproportionally inferior to those of younger patients. We examined medication usage at diagnosis for 171 elderly patients (median age 70 years) with aggressive non-Hodgkin lymphoma treated between 2009 and 2014. At least one potentially inappropriate medication was used in 47% of patients according to the Beers Criteria, 59% experienced treatment delays and/or dose reduction and 65% experienced ≥ grade 3 treatmentrelated toxicities. We report here for the first time that potentially inappropriate medication use was associated with reduced progression-free survival and overall survival, and increased ≥ grade 3 treatment-related toxicities in multivariate analysis.
The incidence of high-grade, aggressive non-Hodgkin lymphoma (NHL) increases with age, yet survival outcomes for elderly patients, defined as aged above 60-65 years, are significantly and disproportionately inferior compared to younger patients (Morrison et al, 2015; Chiappella et al, 2017) . While age-related differences in tumour biology probably play an important role, the management of these patients is heavily influenced by pre-existing comorbidities and geriatric syndromes (Morrison et al, 2015; Chiappella et al, 2017) . Compounding these challenges is the lack of randomized trial data to guide treatment decision-making and assess the risk-benefit ratio of various therapies, as frail patients are generally excluded from pivotal drug trials (Scher & Hurria, 2012) .
Available evidence suggests that geriatric frailty, as determined by the comprehensive geriatric assessment, is an independent predictor of mortality and treatment-related toxicities in several haematological malignancies including high-grade NHL (Hamaker et al, 2014; Lin et al, 2017) . However, even frail patients still appear to benefit substantially from curative intent chemotherapy rather than palliative treatments (Lin et al, 2017) . In addition, it is unclear how geriatric syndrome contributes to outcomes. A systematic review found that increasing numbers of comorbidities adversely affect survival in NHL (Terret et al, 2015) , and similar studies have identified poor nutrition, low haemoglobin and frailty as risk factors for early treatment withdrawal and poor outcome (Aaldriks et al, 2015; Park et al, 2015) .
In this study, we investigated whether potentially inappropriate medication (PIM) use is associated with adverse outcomes in elderly lymphoma patients. We evaluated elderly patients with aggressive NHL who were diagnosed and treated at New York University (NYU) Langone Medical Centeraffiliated Tisch and Bellevue Hospitals, and correlated patient demographics, laboratory characteristics, Charlson Comorbidity Index (CCI) (Charlson et al, 1987) and medication use at the time of diagnosis with progression-free survival (PFS), overall survival (OS), treatment delays/dose reductions and treatment-related ≥ grade 3 toxicities.
Methods

Study population
The study was approved by the institutional review board at NYU School of Medicine. Study subjects were patients aged 60 years or older with aggressive NHL diagnosed and treated with curative intent between 1 January 2009 and 31 December 2014. Charts were reviewed by three investigators and the data were extracted in a de-identified fashion. Aggressive NHL was defined according to the 2008 World Health Organization classification, including diffuse large B cell lymphoma (DLBCL), Burkitt lymphoma, high-grade T-cell lymphomas and blastic mantle cell lymphoma.
Outcome measures
The prescription medication list at the time of diagnosis was obtained for each patient from their electronic medical record. Eye drops, mouthwash, topical creams, and non-prescription vitamins and supplements were excluded. PIMs were defined according to the revised Beers' Criteria (The American Geriatrics Society 2015 Beers Criteria Update Expert Panel, 2015) . Other predictor variables included number of medications, International Prognostic Index (IPI), CCI excluding lymphoma, demographic characteristics and laboratory data. Treatment outcomes include treatment delays, dose reductions, and toxicities as defined by the Common Terminology Criteria for Adverse Events (CTCAE) v4.0 criteria (https://ctep.cancer.gov/protocolDevelopment/electronic_a pplications/ctc.htm#ctc_40; accessed 21 July 2017). PFS and OS were defined as the time between the date of starting chemotherapy and the date of disease progression or death, respectively. Patients not experiencing either event were censored at the latest follow-up. The follow-up cut-off date was 31 December 2016.
Statistical analysis
Statistical analysis was performed using STATA 10 (StataCorp LLC., College Station, TX). Descriptive statistics included means, medians, range and proportions. Analysis of bivariate relationships of continuous variables was performed using Fisher's z-transformation for Pearson's productmoment correlation. Analyses of PFS and OS included Kaplan-Meier estimates and log-rank tests. A multivariate Cox proportional hazards model was built to estimate hazard ratios (HRs) of PFS and OS with 95% confidence intervals (CI). The associations between the risk of treatment-related delay/dose reduction/toxicities and patient characteristics were analysed by odds ratios (ORs) and 95% CIs using logistic regression models. All multivariate analyses were performed with variables that were considered significant factors (P < 0Á20) in the univariate analysis, with and without PIM. Statistical significance was defined as P < 0Á05.
Results
Baseline characteristics
In total, 171 patients were included in the final analysis (141 patients from Tisch Hospital and 30 patients from Bellevue Hospital). The median age of the cohort was 70 years (interquartile range [IQR] 65-77 years). Female patients accounted for 49% of the cohort. The median CCI was 3 (IQR 2-4) and the median IPI was 3 (IQR 2-3). DLBCL accounted for the majority of cases (n = 132, 77%). The median number of medications taken at diagnosis was 4 (IQR 2-7). Almost half of the cohort (n = 81, 47%) were treated with at least one PIM. Of these patients, 42 (52%) were female, 63 (78%) were treated with one, and 18 (22%) received two PIMs. The majority of PIM used were gastrointestinal agents, such as metoclopramide and proton pump inhibitors (N = 47, 58%), or central nervous system agents, such as benzodiazepines and tricyclics (n = 19, 23%). Other groups of PIMs included anticholinergics, non-steroidal anti-inflammatory drugs, short-acting insulin and oral hypoglycaemic agents, and highrisk cardiovascular medications (Table I) . Baseline characteristics were equally matched at both hospitals in terms of age, gender, comorbidities, mediations and treatments except that Bellevue patients had a higher IPI (Table SI) .
Treatment-related toxicities
All patients received curative intent chemo-immunotherapy. Most received CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone)/RCHOP(CHOP + rituximab)-based therapy (n = 151, 88%). A small percentage of patients received R-Da-EPOCH (rituximab + dose-adjusted etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin), hyper-CVAD (hyper-fractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone + methotrexate and cytarabine), high dose methotrexate, or other less common regimens (n = 20, 12%). One hundred and one patients (59%) experienced treatment delay and/or dose reduction during their therapy and 112 patients (65%) experienced ≥ grade 3 treatment-related toxicities. Table II shows the multivariate analysis of treatment delays/dose reductions as well as ≥ grade 3 treatment-related toxicities using logistic regression model. Albumin level and IPI were significant independent predictors of treatment delays/dose reductions while PIM use was a predictor of borderline significance (P = 0Á053). For ≥ grade 3 treatment-related toxicities, albumin level (P < 0Á001) and PIM (P = 0Á014) use were significant, independent predictors.
Survival outcomes
The median length of follow-up was 28 months, during which 41 patients died (24%). PIM use was associated with significantly inferior PFS (P < 0Á001) and OS (P = 0Á008) in log-rank tests. In multivariate analysis of PFS and OS after adjustment for multiple variables, white blood cell (WBC) count, IPI and PIM use remained independent predictors of PFS (Table III) , of which PIM use was the strongest predictor (HR 2Á81; 95% CI 1Á36-5Á81, P = 0Á005). Multivariate analysis of OS, age, gender, WBC count, IPI and PIM use were identified as statistically significant predictors (Table III) . Again, PIM use was the strongest predictor of OS (HR 3Á12; 95% CI 1Á49-6Á52, P = 0Á003).
Discussion
Our findings provide the first significant insight into the contribution of PIM to inferior clinical outcomes. In our cohort of elderly patients (median age 70), with intermediate risk disease (median IPI 3) and moderate comorbidities (median CCI 3), treatment with PIM was common at diagnosis (47%). Nearly a quarter of patients were treated with more than one PIM. Most importantly, PIM use remained an independent predictor of PFS, OS and treatment-related, high-grade toxicities in multivariate analysis. Only one prior study examined medication use in 150 elderly patients with acute myeloid leukaemia undergoing induction chemotherapy and found that polypharmacy was associated with increased 30-day and overall mortality (Elliot et al, 2014) . In the same study, PIM use was not associated with adverse outcomes; however, the Beers criteria used in the study was outdated.
We hypothesize that treatment with PIM may contribute to reduced survival and increased toxicities through a combination of following pathways. It is possible that PIM use is a marker of underlying comorbidities. This notion is supported by the finding that factors associated with increased number of prescription medications among older cancer patients included comorbidity, functional status and PIM use (Prithviraj et al, 2012) . However, in our multivariate analyses, PIM use independently stratifies survival and toxicity outcomes after adjusting for CCI. Second, given that physiological changes of aging significantly impact pharmacokinetics and pharmacodynamics of drugs (Prithviraj et al, 2012; Sharma et al, 2016) , drug-drug interactions associated with PIM may contribute to increased treatment-related toxicities. Finally, PIM, such as central nervous system agents and anticholinergics, may exacerbate the long-term sequela of intensive chemotherapy, such as cognitive decline and physical deconditioning .
Our study has limitations and far-reaching implications. We describe an independent association between PIM use and survival outcomes and treatment toxicities, but a direct causal relationship could not be inferred from these results. Additionally, although our study includes data from two hospitals, the sample size is modest, and may be underpowered CNS agents/Benzodiazepines/TCA, n (%) 19 (23) Anticholinergics, n (%) 6 (7) GI agents/PPI/Metoclopramide, n (%) 47 (58) NSAIDs/other pain medications, n (%) 9 (11) Insulin/other DM medications, n (%) 9 (11) CV medications, n (%) 6 (7) CNS, central nervous system; CV, cardiovascular; DLBCL, diffuse large B cell lymphoma; DM, diabetic mellitus; GI, gastrointestinal; IQR, interquartile range; NHL, non-Hodgkin lymphoma; NSAIDs, non-steroidal anti-inflammatory medications; PIM, potentially inappropriate medication; PPI, proton pump inhibitor; TCA, tricyclic antidepressants. 0Á23-0Á87  0Á018  0Á26  0Á12-0Á54  0Á000  IPI  1Á48  1Á04-2Á11  0Á028  ---PIM use  1Á95  0Á99-3Á84  0Á053  1Á02  1Á00-1Á04  0Á014 CI, confidence interval; IPI, international prognostic index; OR, odds ratio; PIM, potentially inappropriate medication. to fully elucidate contributions of specific PIM drug classes. However, our findings could lead to easily implemented, geriatric-oriented, quality improvement programs for elderly patients, such as PIM screening and de-prescribing practice (Sharma et al, 2016) , or a pharmacist-led, longitudinal medication management program (Nightingale et al, 2015) . Geriatric principle-based, meticulous medication management should become standard of care for these patients.
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Key points
• Potentially inappropriate medication use at diagnosis is associated with inferior progression-free and overall survival of elderly patients with aggressive non-Hodgkin lymphoma.
• Potentially inappropriate medication use at diagnosis predicts grade 3 or higher treatment-related toxicities in elderly patients with aggressive non-Hodgkin lymphoma.
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